GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD.
Tuegel, Courtney; Katz, Ronit; Alam, Mariam; Bhat, Zeenat; Bellovich, Keith; de Boer, Ian; Brosius, Frank; Gadegbeku, Crystal; Gipson, Debbie; Hawkins, Jennifer; Himmelfarb, Jonathan; Ju, Wenjun; Kestenbaum, Bryan; Kretzler, Matthias; Robinson-Cohen, Cassianne; Steigerwalt, Susan; Bansal, Nisha.
Am J Kidney Dis
; 72(4): 519-528, 2018 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-29866459
Growth Differentiation Factor-15 and Risk of CKD Progression.
Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease.
Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease.
Growth Differentiation Factor 15, Its 12-Month Relative Change, and Risk of Cardiovascular Events and Total Mortality in Patients with Stable Coronary Heart Disease: 10-Year Follow-up of the KAROLA Study.
Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study.
Biomarkers of cardiovascular stress and incident chronic kidney disease.
Relation between soluble ST2, growth differentiation factor-15, and high-sensitivity troponin I and incident atrial fibrillation.
Preoperative plasma growth-differentiation factor-15 for prediction of acute kidney injury in patients undergoing cardiac surgery.
Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure.
State of the Art: Blood Biomarkers for Risk Stratification in Patients with Stable Ischemic Heart Disease.